FDA’s Risk/Benefit Decisions Will Be Quantified With Metric From Contractor
Executive Summary
A recent request for proposals may signal a shift in FDA's approach to risk/benefit analysis and views on outcome measures, a move some see as bringing more transparency while also shielding the agency from criticism
You may also be interested in...
PDUFA V: Patients’ Opinions Could Get Formal Role In Review Decisions
FDA is looking to formally add patient perspectives to its analyses in drug application reviews as it continues exploring a more transparent risk-benefit analysis.
PDUFA V: Patients’ Opinions Could Get Formal Role In Review Decisions
FDA is looking to formally add patient perspectives to its analyses in drug application reviews as it continues exploring a more transparent risk-benefit analysis.
Death Vs. Symptomatic Relief – Weighing Risks And Benefits For Asthma Drugs
When discussing a drug's benefits and risks, there is more to the equation than just death, Judith Kramer, Duke University, pointed out during a meeting of three FDA advisory committees to discuss asthma indications for long-acting beta agonists